PROBNP II, N-TERMINAL PRO B-TYPE NATRIURETIC PEPTIDE 04842464190

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed from a foreign,health professional,u report with the FDA on 2017-04-28 for PROBNP II, N-TERMINAL PRO B-TYPE NATRIURETIC PEPTIDE 04842464190 manufactured by Roche Diagnostics.

Event Text Entries

[74057169] (b)(4). This event occurred in (b)(6).
Patient Sequence No: 1, Text Type: N, H10


[74057170] The customer received questionable elecsys probnp ii immunoassay results for one patient from a 6000 e 601 module. The serial number was requested but was not provided. The patient sample repeatedly had a result of <0. 6 pmol/l with a data flag and the result was reported outside the laboratory. The treating physician questioned if it is plausible to have this result for a patient. There was no allegation of an adverse event. The patient was not known to have the clinical symptoms related to heart failure. The patient has been investigated for lung function (a-typcial thorax complaints), has normal glucose values, and a cholesterol value of 5 (no unit of measure provided). No previous pro-bnp or troponin results were known for the patient. The patient has a family history of heart failure and the patient fears he will have heart failure as well. The father of the patient died from heart failure and the brother of the patient had a non-lethal heart attack. Interference or an nt-probnp genetic variant was suspected for the patient. Sample from the patient was submitted for investigation.
Patient Sequence No: 1, Text Type: D, B5


[117967945] A specific root cause could not be determined. Sample from the patient was submitted for investigation and the customer? S low result was confirmed. Further testing of the patient sample found it did not contain the genetic mutations (r72h and e69d). The sample was then tested with the gen 1 probnp assay which uses a polyclonal antibody instead of the monoclonal antibody used in the gen 2 assay. The result was negative for probnp. The results after the sample was treated with heterophilic blocking tubes (hbt) indicated no interference with igm. Further testing showed that an interference with ruthenium was very unlikely. The sample was then tested for probnp on a siemens immulite and the result was 172 ng/l and was clearly above the cut off value. Further clarification of the discrepancy was not possible with the available methods and the current state of the art.
Patient Sequence No: 1, Text Type: N, H10


MAUDE Entry Details

Report Number1823260-2017-00917
MDR Report Key6529225
Report SourceFOREIGN,HEALTH PROFESSIONAL,U
Date Received2017-04-28
Date of Report2017-07-06
Date of Event2017-04-06
Date Mfgr Received2017-04-07
Date Added to Maude2017-04-28
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactNA MICHAEL LESLIE
Manufacturer Street9115 HAGUE ROAD NA
Manufacturer CityINDIANAPOLIS IN 46250
Manufacturer CountryUS
Manufacturer Postal46250
Manufacturer Phone3175214343
Manufacturer G1ROCHE DIAGNOSTICS GMBH
Manufacturer StreetSANDHOFERSTRASSE 116 NA
Manufacturer CityMANNHEIM (BADEN-WURTTEMBERG) 68305
Manufacturer CountryGM
Manufacturer Postal Code68305
Single Use3
Previous Use Code3
Removal Correction NumberNA
Event Type3
Type of Report3

Device Details

Brand NamePROBNP II, N-TERMINAL PRO B-TYPE NATRIURETIC PEPTIDE
Generic NameTEST,NATRIURETIC PEPTIDE
Product CodeNBC
Date Received2017-04-28
Model NumberNA
Catalog Number04842464190
Lot NumberASKU
ID NumberNA
OperatorHEALTH PROFESSIONAL
Device AvailabilityY
Device AgeDA
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerROCHE DIAGNOSTICS
Manufacturer Address9115 HAGUE ROAD NA INDIANAPOLIS IN 462500457 US 462500457


Patients

Patient NumberTreatmentOutcomeDate
10 2017-04-28

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.